PC3 - Investment JSC (HNX:PIC)

CTI BioPharma Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	142,648	116,731	137,854	149,383	127,378	101,559
Revenue Growth (YoY)	20.84%	-15.32%	-7.72%	17.28%	25.42%	3.24%
Selling, General & Admin	15,121	15,265	17,858	19,062	13,348	11,603
Other Operating Expenses	68,596	64,990	72,117	76,095	67,280	50,287
Total Operating Expenses	83,717	80,255	89,975	95,157	80,628	61,890
Operating Income	58,931	36,476	47,879	54,226	46,750	39,668
Interest Expense	-2,431	-2,568	-6,741	-10,781	-12,965	-16,476
Interest Income	686.79	579.1	1,673	2,254	1,291	879.42
Net Interest Expense	-1,744	-1,988	-5,068	-8,527	-11,673	-15,596
Currency Exchange Gain (Loss)	-41.8	-41.75	0.95	-	-	-
Other Non-Operating Income (Expenses)	1,931	1,935	-0.76	-126.92	-124.8	-3,210
EBT Excluding Unusual Items	59,076	36,381	42,811	45,572	34,952	20,862
Gain (Loss) on Sale of Assets	-	-	0.01	-	-	-
Pretax Income	59,076	36,381	42,811	45,572	34,952	20,862
Income Tax Expense	10,232	4,175	4,659	2,695	1,822	1,294
Net Income	48,844	32,206	38,152	42,877	33,130	19,568
Preferred Dividends & Other Adjustments	6,743	3,503	5,364	-	-	-
Net Income to Common	42,101	28,703	32,788	42,877	33,130	19,568
Net Income Growth	93.82%	-15.59%	-11.02%	29.42%	69.31%	6.64%
Shares Outstanding (Basic)	33	33	33	39	33	33
Shares Outstanding (Diluted)	33	33	33	39	33	33
Shares Change (YoY)	7.62%	-	-15.25%	18.02%	-0.01%	5.37%
EPS (Basic)	1262.78	860.92	983.46	1090.00	994.00	587.00
EPS (Diluted)	1262.78	860.92	983.00	1090.00	994.00	587.00
EPS Growth	114.30%	-12.42%	-9.82%	9.66%	69.34%	1.21%
Free Cash Flow	53,001	40,571	67,894	76,771	63,547	40,056
Free Cash Flow Per Share	1589.73	1216.89	2036.43	1951.63	1906.59	1201.62
Dividend Per Share	-	-	1000.000	-	800.000	500.000
Dividend Growth	-	-	-	-	60.00%	-
Profit Margin	29.51%	24.59%	23.79%	28.70%	26.01%	19.27%
Free Cash Flow Margin	37.16%	34.76%	49.25%	51.39%	49.89%	39.44%
EBITDA	97,051	73,676	86,502	93,683	85,056	65,174
EBITDA Margin	68.03%	63.12%	62.75%	62.71%	66.77%	64.17%
D&A For EBITDA	38,120	37,200	38,623	39,457	38,306	25,506
EBIT	58,931	36,476	47,879	54,226	46,750	39,668
EBIT Margin	41.31%	31.25%	34.73%	36.30%	36.70%	39.06%
Effective Tax Rate	17.32%	11.48%	10.88%	5.91%	5.21%	6.20%
Revenue as Reported	142,648	116,731	137,854	149,383	127,378	101,559

Updated Jan 20, 2025. Source: S&P Global Market Intelligence. Utility template. Financial Sources.